Redmile Group, LLC

Q3 2023 13F Holdings Report, Stock Holdings

Signature - Title
Jennifer Ciresi - General Counsel and Chief Compliance Officer
Location
San Francisco, CA
Holdings as of
September 30, 2023
Value $
$2.1B
Num holdings
68
Date filed
11/14/2023, 04:15 PM
Description
All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q2 2023 - Aug 14, 2023
Next filing
Q4 2023 - Feb 14, 2024
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2023 Q3 compared to 2023 Q2 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Jennifer Ciresi General Counsel and Chief Compliance Officer San Francisco, California 11/14/2023

The attached information table excludes (a) 3,628 shares of common stock of IGM BIOSCIENCES INC issued pursuant to restricted stock unit awards, (b) 11,331 shares of common stock of FATE THERAPEUTICS INC issued pursuant to restricted stock unit awards, (c) 40,983 shares of common stock of SCIENCE 37 HOLDINGS, INC. issued pursuant to restricted stock unit awards and (d) 2,092 of common stock of AUGMEDIX, INC. issued pursuant to restricted stock unit awards.